Effectiveness and Safety of Enbrel® (etanercept) in Rheumatoid Arthritis Subjects who have Failed Remicade® (infliximab)

- Adults with RA (ACR criteria) for greater than or equal to 6 months - Infliximab treatment for at least 18 weeks - Infliximab infusion prior to screening at an increased dosing regimen: 5 mg/kg every 4-8 weeks (dose), OR, 3 mg/kg every 4-6 weeks (frequency) - Failing infliximab defined by ALL of the following at screening and baseline visit: Disease Activity Score (DAS 28) greater than or equal to 4.5, greater than or equal to 5 swollen joints, greater than or equal to 5 tender joints - Subjects must be receiving stable methotrexate (MTX), at a dose of greater than or equal to 10 mg/week at least 10 weeks prior to screening - Stable disease modifying anti-rheumatic drugs (DMARD) therapy (including sulfasalazine, hydroxychloroquine), greater than or equal to 8 weeks prior to screening - Stable dose corticosteroids, less than 10 mg/day at greater than or equal to 4 weeks prior to screening - Stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) greater than or equal to 1 week prior to screening

- ACR functional class IV - Prior treatment with etanercept - Receipt of any investigational drug/biologic within 28 days of study drug initiation - Active infection or predisposition to infection - Elective surgery planned during study period - Intra-articular, soft tissue, or intramuscular corticosteroid injections during 4 weeks prior to screening - Contraindications to etanercept as defined in the package insert - Severe co-morbidities: History of cancer within 5 years; Diagnosis of class III or IV congestive heart failure (CHF); Uncontrolled hypertension (HTN); CNS-demyelinating events suggestive of multiple sclerosis (MS); Known HIV-positive status; Oxygen-dependent pulmonary status; Chronic hepatitis B or C; Systemic Lupus Erythematosus (SLE); Active or prior history of tuberculosis (TB) (or known exposure) or positive PPD without adequate TB prophylaxis